Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Comparison 1 Global Rating OC, Outcome 1 Global Rating (no change or improvement at 3 months) OC.
Figuras y tablas -
Analysis 1.1

Comparison 1 Global Rating OC, Outcome 1 Global Rating (no change or improvement at 3 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Global Rating OC, Outcome 2 Global Rating (no change or improvement at 6 months) OC.
Figuras y tablas -
Analysis 1.2

Comparison 1 Global Rating OC, Outcome 2 Global Rating (no change or improvement at 6 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 ADAS‐cog (Change from baseline) OC, Outcome 1 ADAS‐cog (Change from baseline at 3 months) OC.
Figuras y tablas -
Analysis 2.1

Comparison 2 ADAS‐cog (Change from baseline) OC, Outcome 1 ADAS‐cog (Change from baseline at 3 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 ADAS‐cog (Change from baseline) OC, Outcome 2 ADAS‐cog (Change from baseline at 6 months) OC.
Figuras y tablas -
Analysis 2.2

Comparison 2 ADAS‐cog (Change from baseline) OC, Outcome 2 ADAS‐cog (Change from baseline at 6 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 ADAS‐cog (4 points or more improvement) OC, Outcome 1 ADAS‐cog (4 points or more improvement at 3 months) OC.
Figuras y tablas -
Analysis 3.1

Comparison 3 ADAS‐cog (4 points or more improvement) OC, Outcome 1 ADAS‐cog (4 points or more improvement at 3 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 3 ADAS‐cog (4 points or more improvement) OC, Outcome 2 ADAS‐cog (4 points or more improvement at 6 months) OC.
Figuras y tablas -
Analysis 3.2

Comparison 3 ADAS‐cog (4 points or more improvement) OC, Outcome 2 ADAS‐cog (4 points or more improvement at 6 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 4 ADCS‐ADL (Change from baseline) OC, Outcome 1 ADCS/ADL (Change from baseline at 6 months) OC.
Figuras y tablas -
Analysis 4.1

Comparison 4 ADCS‐ADL (Change from baseline) OC, Outcome 1 ADCS/ADL (Change from baseline at 6 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 NPI (Change from baseline) OC, Outcome 1 NPI (Change from baseline at 3 months) OC.
Figuras y tablas -
Analysis 5.1

Comparison 5 NPI (Change from baseline) OC, Outcome 1 NPI (Change from baseline at 3 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 5 NPI (Change from baseline) OC, Outcome 2 NPI (Change from baseline at 6 months) OC.
Figuras y tablas -
Analysis 5.2

Comparison 5 NPI (Change from baseline) OC, Outcome 2 NPI (Change from baseline at 6 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 DAD (Change from baseline) OC, Outcome 1 DAD (Change from baseline at 3 months) OC.
Figuras y tablas -
Analysis 6.1

Comparison 6 DAD (Change from baseline) OC, Outcome 1 DAD (Change from baseline at 3 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 6 DAD (Change from baseline) OC, Outcome 2 DAD (Change from baseline at 6 months) OC.
Figuras y tablas -
Analysis 6.2

Comparison 6 DAD (Change from baseline) OC, Outcome 2 DAD (Change from baseline at 6 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Global Rating ITT, Outcome 1 Global Rating (no change or improvement at 3 months) ITT.
Figuras y tablas -
Analysis 7.1

Comparison 7 Global Rating ITT, Outcome 1 Global Rating (no change or improvement at 3 months) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 7 Global Rating ITT, Outcome 2 Global Rating (no change or improvement at 6 months) ITT.
Figuras y tablas -
Analysis 7.2

Comparison 7 Global Rating ITT, Outcome 2 Global Rating (no change or improvement at 6 months) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 ADAS‐cog (Change from baseline) ITT, Outcome 1 ADAS‐cog (Change from baseline at 3 months) ITT.
Figuras y tablas -
Analysis 8.1

Comparison 8 ADAS‐cog (Change from baseline) ITT, Outcome 1 ADAS‐cog (Change from baseline at 3 months) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 ADAS‐cog (Change from baseline) ITT, Outcome 2 ADAS‐cog (Change from baseline at 6 months) ITT.
Figuras y tablas -
Analysis 8.2

Comparison 8 ADAS‐cog (Change from baseline) ITT, Outcome 2 ADAS‐cog (Change from baseline at 6 months) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 ADAS‐cog (Change from baseline) ITT, Outcome 3 ADAS‐cog (Change from baseline at 12 months in MCI) ITT.
Figuras y tablas -
Analysis 8.3

Comparison 8 ADAS‐cog (Change from baseline) ITT, Outcome 3 ADAS‐cog (Change from baseline at 12 months in MCI) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 8 ADAS‐cog (Change from baseline) ITT, Outcome 4 ADAS‐cog (Change from baseline at 24 months in MCI) ITT.
Figuras y tablas -
Analysis 8.4

Comparison 8 ADAS‐cog (Change from baseline) ITT, Outcome 4 ADAS‐cog (Change from baseline at 24 months in MCI) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 9 ADAS‐cog (4 point or more improvement) ITT, Outcome 1 ADAS‐cog (4 points or more improvement at 3 months) OC.
Figuras y tablas -
Analysis 9.1

Comparison 9 ADAS‐cog (4 point or more improvement) ITT, Outcome 1 ADAS‐cog (4 points or more improvement at 3 months) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 10 ADCS‐ADL (Change from baseline) ITT, Outcome 1 ADCS/ADL (Change from baseline at 6 months) ITT.
Figuras y tablas -
Analysis 10.1

Comparison 10 ADCS‐ADL (Change from baseline) ITT, Outcome 1 ADCS/ADL (Change from baseline at 6 months) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 NPI (Change from baseline) ITT, Outcome 1 NPI (Change from baseline at 3 months) ITT.
Figuras y tablas -
Analysis 11.1

Comparison 11 NPI (Change from baseline) ITT, Outcome 1 NPI (Change from baseline at 3 months) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 11 NPI (Change from baseline) ITT, Outcome 2 NPI (Change from baseline at 6 months) ITT.
Figuras y tablas -
Analysis 11.2

Comparison 11 NPI (Change from baseline) ITT, Outcome 2 NPI (Change from baseline at 6 months) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 DAD (Change from baseline) ITT, Outcome 1 DAD (Change from baseline at 3 months) ITT.
Figuras y tablas -
Analysis 12.1

Comparison 12 DAD (Change from baseline) ITT, Outcome 1 DAD (Change from baseline at 3 months) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 12 DAD (Change from baseline) ITT, Outcome 2 DAD (Change from baseline at 6 months) ITT.
Figuras y tablas -
Analysis 12.2

Comparison 12 DAD (Change from baseline) ITT, Outcome 2 DAD (Change from baseline at 6 months) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Global Rating dose analyses OC, Outcome 1 Global Rating (no change or improvement; 8 mg) OC.
Figuras y tablas -
Analysis 13.1

Comparison 13 Global Rating dose analyses OC, Outcome 1 Global Rating (no change or improvement; 8 mg) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Global Rating dose analyses OC, Outcome 2 Global Rating (no change or improvement 16‐24mg/d) OC.
Figuras y tablas -
Analysis 13.2

Comparison 13 Global Rating dose analyses OC, Outcome 2 Global Rating (no change or improvement 16‐24mg/d) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Global Rating dose analyses OC, Outcome 3 Global Rating (no change or improvement 24mg/d to 24‐32mg/d) OC.
Figuras y tablas -
Analysis 13.3

Comparison 13 Global Rating dose analyses OC, Outcome 3 Global Rating (no change or improvement 24mg/d to 24‐32mg/d) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 13 Global Rating dose analyses OC, Outcome 4 Global Rating (no change or improvement 32‐36mg/d) OC.
Figuras y tablas -
Analysis 13.4

Comparison 13 Global Rating dose analyses OC, Outcome 4 Global Rating (no change or improvement 32‐36mg/d) OC.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 Global Rating dose analyses ITT, Outcome 1 Global Rating (no change or improvement; 8 mg) ITT.
Figuras y tablas -
Analysis 14.1

Comparison 14 Global Rating dose analyses ITT, Outcome 1 Global Rating (no change or improvement; 8 mg) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 Global Rating dose analyses ITT, Outcome 2 Global Rating (no change or improvement 16‐24mg/d) ITT.
Figuras y tablas -
Analysis 14.2

Comparison 14 Global Rating dose analyses ITT, Outcome 2 Global Rating (no change or improvement 16‐24mg/d) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 Global Rating dose analyses ITT, Outcome 3 Global Rating (no change or improvement 24mg/d to 24‐32mg/d) ITT.
Figuras y tablas -
Analysis 14.3

Comparison 14 Global Rating dose analyses ITT, Outcome 3 Global Rating (no change or improvement 24mg/d to 24‐32mg/d) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 14 Global Rating dose analyses ITT, Outcome 4 Global Rating (no change or improvement 32‐36mg/d) ITT.
Figuras y tablas -
Analysis 14.4

Comparison 14 Global Rating dose analyses ITT, Outcome 4 Global Rating (no change or improvement 32‐36mg/d) ITT.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 15 Conversion from MCI to dementia (change of CDR‐SB from 0.5 to >=1) ITT, Outcome 2 Conversion from MCI to dementia at 24 months.
Figuras y tablas -
Analysis 15.2

Comparison 15 Conversion from MCI to dementia (change of CDR‐SB from 0.5 to >=1) ITT, Outcome 2 Conversion from MCI to dementia at 24 months.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 Withdrawals before end of treatment, Outcome 1 Proportion of all cause discontinuations (3 months).
Figuras y tablas -
Analysis 16.1

Comparison 16 Withdrawals before end of treatment, Outcome 1 Proportion of all cause discontinuations (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 Withdrawals before end of treatment, Outcome 2 Proportion of discontinuations due to adverse events (3 months).
Figuras y tablas -
Analysis 16.2

Comparison 16 Withdrawals before end of treatment, Outcome 2 Proportion of discontinuations due to adverse events (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 Withdrawals before end of treatment, Outcome 3 Proportion of all cause discontinuations (6 months).
Figuras y tablas -
Analysis 16.3

Comparison 16 Withdrawals before end of treatment, Outcome 3 Proportion of all cause discontinuations (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 16 Withdrawals before end of treatment, Outcome 4 Proportion of discontinuations due to adverse events (6 months).
Figuras y tablas -
Analysis 16.4

Comparison 16 Withdrawals before end of treatment, Outcome 4 Proportion of discontinuations due to adverse events (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 1 Proportion of subjects experiencing nausea (3 months).
Figuras y tablas -
Analysis 17.1

Comparison 17 Specific adverse events (3 months), Outcome 1 Proportion of subjects experiencing nausea (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 2 Proportion of subjects experiencing vomiting (3 months).
Figuras y tablas -
Analysis 17.2

Comparison 17 Specific adverse events (3 months), Outcome 2 Proportion of subjects experiencing vomiting (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 3 Proportion of subjects experiencing dizziness (3 months).
Figuras y tablas -
Analysis 17.3

Comparison 17 Specific adverse events (3 months), Outcome 3 Proportion of subjects experiencing dizziness (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 4 Proportion of subjects experiencing diarrhea (3 months).
Figuras y tablas -
Analysis 17.4

Comparison 17 Specific adverse events (3 months), Outcome 4 Proportion of subjects experiencing diarrhea (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 5 Proportion of subjects experiencing anorexia (3 months).
Figuras y tablas -
Analysis 17.5

Comparison 17 Specific adverse events (3 months), Outcome 5 Proportion of subjects experiencing anorexia (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 6 Proportion of subjects experiencing somnolence (3 months).
Figuras y tablas -
Analysis 17.6

Comparison 17 Specific adverse events (3 months), Outcome 6 Proportion of subjects experiencing somnolence (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 7 Proportion of subjects experiencing abdominal pain (3 months).
Figuras y tablas -
Analysis 17.7

Comparison 17 Specific adverse events (3 months), Outcome 7 Proportion of subjects experiencing abdominal pain (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 8 Proportion of subjects experiencing decreased appetite (3 months).
Figuras y tablas -
Analysis 17.8

Comparison 17 Specific adverse events (3 months), Outcome 8 Proportion of subjects experiencing decreased appetite (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 9 Proportion of subjects experiencing agitation (3 months).
Figuras y tablas -
Analysis 17.9

Comparison 17 Specific adverse events (3 months), Outcome 9 Proportion of subjects experiencing agitation (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 17 Specific adverse events (3 months), Outcome 10 Proportion of subjects experiencing headache (3 months).
Figuras y tablas -
Analysis 17.10

Comparison 17 Specific adverse events (3 months), Outcome 10 Proportion of subjects experiencing headache (3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 1 Proportion of subjects experiencing nausea (6 months).
Figuras y tablas -
Analysis 18.1

Comparison 18 Specific adverse events (6 months), Outcome 1 Proportion of subjects experiencing nausea (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 2 Proportion of subjects experiencing vomiting (6 months).
Figuras y tablas -
Analysis 18.2

Comparison 18 Specific adverse events (6 months), Outcome 2 Proportion of subjects experiencing vomiting (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 3 Proportion of subjects experiencing dizziness (6 months).
Figuras y tablas -
Analysis 18.3

Comparison 18 Specific adverse events (6 months), Outcome 3 Proportion of subjects experiencing dizziness (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 4 Proportion of subjects experiencing diarrhea (6 months).
Figuras y tablas -
Analysis 18.4

Comparison 18 Specific adverse events (6 months), Outcome 4 Proportion of subjects experiencing diarrhea (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 5 Proportion of subjects experiencing anorexia (6 months).
Figuras y tablas -
Analysis 18.5

Comparison 18 Specific adverse events (6 months), Outcome 5 Proportion of subjects experiencing anorexia (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 6 Proportion of subjects experiencing weight loss (6 months).
Figuras y tablas -
Analysis 18.6

Comparison 18 Specific adverse events (6 months), Outcome 6 Proportion of subjects experiencing weight loss (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 7 Proportion of subjects experiencing abdominal pain (6 months).
Figuras y tablas -
Analysis 18.7

Comparison 18 Specific adverse events (6 months), Outcome 7 Proportion of subjects experiencing abdominal pain (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 8 Proportion of subjects experiencing tremor (6 months).
Figuras y tablas -
Analysis 18.8

Comparison 18 Specific adverse events (6 months), Outcome 8 Proportion of subjects experiencing tremor (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 9 Proportion of subjects experiencing agitation (6 months).
Figuras y tablas -
Analysis 18.9

Comparison 18 Specific adverse events (6 months), Outcome 9 Proportion of subjects experiencing agitation (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 18 Specific adverse events (6 months), Outcome 10 Proportion of subjects experiencing headache (6 months).
Figuras y tablas -
Analysis 18.10

Comparison 18 Specific adverse events (6 months), Outcome 10 Proportion of subjects experiencing headache (6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 19 Proportion of subjects deceased, Outcome 1 Proportion of subjects deceased ( 3 months).
Figuras y tablas -
Analysis 19.1

Comparison 19 Proportion of subjects deceased, Outcome 1 Proportion of subjects deceased ( 3 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 19 Proportion of subjects deceased, Outcome 2 Proportion of subjects deceased ( 6 months).
Figuras y tablas -
Analysis 19.2

Comparison 19 Proportion of subjects deceased, Outcome 2 Proportion of subjects deceased ( 6 months).

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 19 Proportion of subjects deceased, Outcome 3 Proportion of subjects deceased ( 24 months in MCI).
Figuras y tablas -
Analysis 19.3

Comparison 19 Proportion of subjects deceased, Outcome 3 Proportion of subjects deceased ( 24 months in MCI).

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Global Rating OC

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global Rating (no change or improvement at 3 months) OC Show forest plot

2

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

1.1 galantamine (18mg/d bid or tid) vs placebo

1

135

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.96 [0.88, 4.37]

1.2 galantamine (24mg/d bid or tid) vs placebo

1

118

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.73 [0.73, 4.09]

1.3 galantamine (24‐32 mg/d bid or tid) vs placebo

1

281

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.28 [1.33, 3.91]

1.4 galantamine (36mg/d bid or tid) vs placebo

1

103

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.41 [1.22, 9.51]

2 Global Rating (no change or improvement at 6 months) OC Show forest plot

6

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

2.1 galantamine (8mg/d bid) vs placebo

1

340

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.13 [0.71, 1.79]

2.2 galantamine (16mg/d bid) vs placebo

1

445

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.25 [1.55, 3.28]

2.3 galantamine (16‐24mg/d bid) vs placebo

1

499

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.18 [0.83, 1.69]

2.4 galantamine (16‐24mg/d Prolonged Release) vs placebo

1

505

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.19 [0.83, 1.70]

2.5 galantamine (24mg/d bid) vs placebo

4

1314

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.05 [1.64, 2.56]

2.6 galantamine (32mg/d bid) vs placebo

2

606

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.94 [1.40, 2.69]

2.7 galantamine (32mg/d tds) vs placebo

1

414

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.30 [0.87, 1.94]
Figuras y tablas -
Comparison 1. Global Rating OC
Ir a la tabla de la revisión
Comparison 2. ADAS‐cog (Change from baseline) OC

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 ADAS‐cog (Change from baseline at 3 months) OC Show forest plot

4

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 galantamine (18mg/d bid) vs placebo

1

115

Mean Difference (IV, Fixed, 95% CI)

‐3.10 [‐5.45, ‐0.75]

1.2 galantamine (16‐24mg/d bid) vs placebo

1

543

Mean Difference (IV, Fixed, 95% CI)

‐2.6 [‐3.47, ‐1.73]

1.3 galantamine (16‐24mg/d Prolonged Release) vs placebo

1

544

Mean Difference (IV, Fixed, 95% CI)

‐2.2 [‐3.09, ‐1.31]

1.4 galantamine (24mg/d bid) vs placebo

1

97

Mean Difference (IV, Fixed, 95% CI)

‐4.20 [‐6.84, ‐1.56]

1.5 galantamine (24‐32 mg/d bid) vs placebo

1

278

Mean Difference (IV, Fixed, 95% CI)

‐1.90 [‐3.04, ‐0.76]

1.6 galantamine (32mg/d tds) vs placebo

1

398

Mean Difference (IV, Fixed, 95% CI)

‐2.4 [‐3.65, ‐1.15]

1.7 galantamine (36mg/d bid) vs placebo

1

82

Mean Difference (IV, Fixed, 95% CI)

‐4.1 [‐6.60, ‐1.60]

2 ADAS‐cog (Change from baseline at 6 months) OC Show forest plot

6

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

2.1 galantamine (8mg/d bid) vs placebo

1

351

Mean Difference (IV, Fixed, 95% CI)

‐1.7 [‐3.02, ‐0.38]

2.2 galantamine (16mg/d bid) vs placebo

1

433

Mean Difference (IV, Fixed, 95% CI)

‐3.3 [‐4.45, ‐2.15]

2.3 galantamine (16‐24mg/d bid) vs placebo

1

475

Mean Difference (IV, Fixed, 95% CI)

‐3.10 [‐4.18, ‐2.02]

2.4 galantamine (16‐24mg/d Prolonged Release) vs placebo

1

488

Mean Difference (IV, Fixed, 95% CI)

‐2.7 [‐3.67, ‐1.73]

2.5 galantamine (24mg/d bid) vs placebo

4

1290

Mean Difference (IV, Fixed, 95% CI)

‐3.38 [‐4.04, ‐2.72]

2.6 galantamine (32mg/d bid or tds) vs placebo

2

599

Mean Difference (IV, Fixed, 95% CI)

‐3.99 [‐4.99, ‐2.99]

2.7 galantamine (32mg/d tds) vs placebo

1

394

Mean Difference (IV, Fixed, 95% CI)

‐2.9 [‐4.29, ‐1.51]
Figuras y tablas -
Comparison 2. ADAS‐cog (Change from baseline) OC
Ir a la tabla de la revisión
Comparison 3. ADAS‐cog (4 points or more improvement) OC

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 ADAS‐cog (4 points or more improvement at 3 months) OC Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

1.3 galantamine (24‐32 mg/d bid or tid) vs placebo

1

270

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.79 [1.04, 3.09]

2 ADAS‐cog (4 points or more improvement at 6 months) OC Show forest plot

3

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

2.1 galantamine (8mg/d bid) vs placebo

1

326

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.44 [0.81, 2.55]

2.2 galantamine (16mg/d bid) vs placebo

1

433

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.24 [1.47, 3.42]

2.3 galantamine (24mg/d bid) vs placebo

3

1051

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.42 [1.83, 3.20]

2.4 galantamine (32mg/d bid) vs placebo

2

597

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.72 [1.86, 3.96]
Figuras y tablas -
Comparison 3. ADAS‐cog (4 points or more improvement) OC
Ir a la tabla de la revisión
Comparison 4. ADCS‐ADL (Change from baseline) OC

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 ADCS/ADL (Change from baseline at 6 months) OC Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 galantamine (8mg/d bid) vs placebo

1

341

Mean Difference (IV, Fixed, 95% CI)

0.90 [‐1.22, 3.02]

1.2 galantamine (16mg/d bid) vs placebo

1

447

Mean Difference (IV, Fixed, 95% CI)

3.50 [1.84, 5.16]

1.3 galantamine (16‐24mg/d bid) vs placebo

1

500

Mean Difference (IV, Fixed, 95% CI)

1.4 [‐1.09, 3.89]

1.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

503

Mean Difference (IV, Fixed, 95% CI)

2.4 [0.80, 4.00]

1.5 galantamine (24mg/d bid) vs placebo

1

447

Mean Difference (IV, Fixed, 95% CI)

2.4 [0.74, 4.06]
Figuras y tablas -
Comparison 4. ADCS‐ADL (Change from baseline) OC
Ir a la tabla de la revisión
Comparison 5. NPI (Change from baseline) OC

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 NPI (Change from baseline at 3 months) OC Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 galantamine (24‐32 mg/d bid or tid) vs placebo

1

282

Mean Difference (IV, Fixed, 95% CI)

‐0.7 [‐4.07, 2.67]

2 NPI (Change from baseline at 6 months) OC Show forest plot

3

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

2.1 galantamine (8mg/d bid) vs placebo

1

340

Mean Difference (IV, Fixed, 95% CI)

0.0 [‐2.55, 2.55]

2.2 galantamine (16mg/d bid) vs placebo

1

445

Mean Difference (IV, Fixed, 95% CI)

‐2.4 [‐4.48, ‐0.32]

2.3 galantamine (16‐24mg/d bid) vs placebo

1

500

Mean Difference (IV, Fixed, 95% CI)

‐1.3 [‐3.59, 0.99]

2.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

503

Mean Difference (IV, Fixed, 95% CI)

‐0.7 [‐2.80, 1.40]

2.5 galantamine (24mg/d bid) vs placebo

2

677

Mean Difference (IV, Fixed, 95% CI)

‐2.09 [‐3.84, ‐0.34]
Figuras y tablas -
Comparison 5. NPI (Change from baseline) OC
Ir a la tabla de la revisión
Comparison 6. DAD (Change from baseline) OC

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 DAD (Change from baseline at 3 months) OC Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 galantamine (24‐32 mg/d bid or tid) vs placebo

1

282

Mean Difference (IV, Fixed, 95% CI)

4.3 [1.46, 7.14]

2 DAD (Change from baseline at 6 months) OC Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

2.1 galantamine (24mg/d bid) vs placebo

2

575

Mean Difference (IV, Fixed, 95% CI)

3.87 [1.34, 6.39]

2.2 galantamine (32mg/d bid) vs placebo

1

334

Mean Difference (IV, Fixed, 95% CI)

3.80 [0.29, 7.31]
Figuras y tablas -
Comparison 6. DAD (Change from baseline) OC
Ir a la tabla de la revisión
Comparison 7. Global Rating ITT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global Rating (no change or improvement at 3 months) ITT Show forest plot

2

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

1.1 galantamine (18mg/d bid) vs placebo

1

162

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.44 [1.18, 5.04]

1.2 galantamine (24mg/d bid) vs placebo

1

136

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.11 [0.96, 4.62]

1.3 galantamine (24‐32 mg/d bid or tid) vs placebo

1

363

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.48 [0.92, 2.37]

1.4 galantamine (36mg/d bid) vs placebo

1

130

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.70 [1.18, 6.17]

2 Global Rating (no change or improvement at 6 months) ITT Show forest plot

6

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

2.1 galantamine (8mg/d bid) vs placebo

1

391

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.17 [0.77, 1.78]

2.2 galantamine (16mg/d bid) vs placebo

1

517

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.04 [1.44, 2.89]

2.3 galantamine (16‐24mg/d bid) vs placebo

1

603

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.27 [0.92, 1.76]

2.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

592

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.20 [0.86, 1.66]

2.5 galantamine (24mg/d bid) vs placebo

4

1570

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.90 [1.55, 2.33]

2.6 galantamine (32mg/d bid) vs placebo

2

768

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.79 [1.34, 2.38]

2.7 galantamine (32mg/d tds) vs placebo

1

525

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.28 [0.89, 1.83]
Figuras y tablas -
Comparison 7. Global Rating ITT
Ir a la tabla de la revisión
Comparison 8. ADAS‐cog (Change from baseline) ITT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 ADAS‐cog (Change from baseline at 3 months) ITT Show forest plot

3

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 galantamine (18mg/d bid) vs placebo

1

163

Mean Difference (IV, Fixed, 95% CI)

‐1.70 [‐3.64, 0.24]

1.2 galantamine (16‐24mg/d bid) vs placebo

1

592

Mean Difference (IV, Fixed, 95% CI)

‐2.7 [‐3.55, ‐1.85]

1.3 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

586

Mean Difference (IV, Fixed, 95% CI)

1.8 [0.94, 2.66]

1.4 galantamine (24mg/d bid) vs placebo

1

137

Mean Difference (IV, Fixed, 95% CI)

‐3.0 [‐5.23, ‐0.77]

1.5 galantamine (24‐32 mg/d bid or tid) vs placebo

1

359

Mean Difference (IV, Fixed, 95% CI)

‐1.70 [‐2.79, ‐0.61]

1.6 galantamine (36mg/d bid) vs placebo

1

133

Mean Difference (IV, Fixed, 95% CI)

‐2.3 [‐4.24, ‐0.36]

2 ADAS‐cog (Change from baseline at 6 months) ITT Show forest plot

6

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

2.1 galantamine (8mg/d bid) vs placebo

1

381

Mean Difference (IV, Fixed, 95% CI)

‐1.30 [‐2.57, ‐0.03]

2.2 galantamine (16mg/d bid ) vs placebo

1

508

Mean Difference (IV, Fixed, 95% CI)

‐3.10 [‐4.13, ‐2.07]

2.3 galantamine (16‐24mg/d bid) vs placebo

1

592

Mean Difference (IV, Fixed, 95% CI)

‐2.8 [‐3.76, ‐1.84]

2.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

587

Mean Difference (IV, Fixed, 95% CI)

‐2.5 [‐3.39, ‐1.61]

2.5 galantamine (24mg/d bid) vs placebo

4

1630

Mean Difference (IV, Fixed, 95% CI)

‐3.13 [‐3.70, ‐2.55]

2.6 galantamine (32mg/d bid) vs placebo

2

825

Mean Difference (IV, Fixed, 95% CI)

‐3.29 [‐4.14, ‐2.44]

2.7 galantamine (32mg/d tds) vs placebo

1

553

Mean Difference (IV, Fixed, 95% CI)

‐2.9 [‐4.01, ‐1.79]

3 ADAS‐cog (Change from baseline at 12 months in MCI) ITT Show forest plot

2

1903

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.62, 0.40]

3.1 galantamine (16‐24mg/d bid) vs placebo in MCI

2

1903

Mean Difference (IV, Fixed, 95% CI)

‐0.11 [‐0.62, 0.40]

4 ADAS‐cog (Change from baseline at 24 months in MCI) ITT Show forest plot

2

1903

Mean Difference (IV, Fixed, 95% CI)

‐0.21 [‐0.78, 0.37]

4.1 galantamine (16‐24mg/d bid) vs placebo in MCI

2

1903

Mean Difference (IV, Fixed, 95% CI)

‐0.21 [‐0.78, 0.37]
Figuras y tablas -
Comparison 8. ADAS‐cog (Change from baseline) ITT
Ir a la tabla de la revisión
Comparison 9. ADAS‐cog (4 point or more improvement) ITT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 ADAS‐cog (4 points or more improvement at 3 months) OC Show forest plot

1

359

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.46 [0.90, 2.39]
Figuras y tablas -
Comparison 9. ADAS‐cog (4 point or more improvement) ITT
Ir a la tabla de la revisión
Comparison 10. ADCS‐ADL (Change from baseline) ITT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 ADCS/ADL (Change from baseline at 6 months) ITT Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 galantamine (8mg/d bid) vs placebo

1

391

Mean Difference (IV, Fixed, 95% CI)

0.60 [‐1.36, 2.56]

1.2 galantamine (16mg/d bid) vs placebo

1

517

Mean Difference (IV, Fixed, 95% CI)

3.10 [1.57, 4.63]

1.3 galantamine (24mg/d bid) vs placebo

1

515

Mean Difference (IV, Fixed, 95% CI)

2.3 [0.64, 3.96]
Figuras y tablas -
Comparison 10. ADCS‐ADL (Change from baseline) ITT
Ir a la tabla de la revisión
Comparison 11. NPI (Change from baseline) ITT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 NPI (Change from baseline at 3 months) ITT Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 galantamine (24‐32 mg/d bid or tid) vs placebo

1

364

Mean Difference (IV, Fixed, 95% CI)

‐0.8 [‐2.67, 1.07]

2 NPI (Change from baseline at 6 months) ITT Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

2.1 galantamine (8mg/d bid) vs placebo

1

391

Mean Difference (IV, Fixed, 95% CI)

0.30 [‐2.09, 2.69]

2.2 galantamine (16mg/d bid) vs placebo

1

517

Mean Difference (IV, Fixed, 95% CI)

‐2.1 [‐4.04, ‐0.16]

2.3 galantamine (24mg/d bid) vs placebo

2

788

Mean Difference (IV, Fixed, 95% CI)

‐1.49 [‐3.11, 0.13]
Figuras y tablas -
Comparison 11. NPI (Change from baseline) ITT
Ir a la tabla de la revisión
Comparison 12. DAD (Change from baseline) ITT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 DAD (Change from baseline at 3 months) ITT Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

1.1 galantamine (24‐32 mg/d bid or tid) vs placebo

1

364

Mean Difference (IV, Fixed, 95% CI)

4.8 [2.05, 7.55]

2 DAD (Change from baseline at 6 months) ITT Show forest plot

2

Mean Difference (IV, Fixed, 95% CI)

Subtotals only

2.1 galantamine (24mg/d bid) vs placebo

2

701

Mean Difference (IV, Fixed, 95% CI)

3.66 [1.41, 5.90]

2.2 galantamine (32mg/d bid) vs placebo

1

424

Mean Difference (IV, Fixed, 95% CI)

3.5 [0.52, 6.48]
Figuras y tablas -
Comparison 12. DAD (Change from baseline) ITT
Ir a la tabla de la revisión
Comparison 13. Global Rating dose analyses OC

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global Rating (no change or improvement; 8 mg) OC Show forest plot

1

340

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.13 [0.71, 1.79]

2 Global Rating (no change or improvement 16‐24mg/d) OC Show forest plot

3

1079

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.63 [1.28, 2.09]

3 Global Rating (no change or improvement 24mg/d to 24‐32mg/d) OC Show forest plot

6

1713

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.06 [1.69, 2.52]

4 Global Rating (no change or improvement 32‐36mg/d) OC Show forest plot

4

1123

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.72 [1.35, 2.20]
Figuras y tablas -
Comparison 13. Global Rating dose analyses OC
Ir a la tabla de la revisión
Comparison 14. Global Rating dose analyses ITT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Global Rating (no change or improvement; 8 mg) ITT Show forest plot

1

391

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.17 [0.77, 1.78]

2 Global Rating (no change or improvement 16‐24mg/d) ITT Show forest plot

3

1282

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.65 [1.32, 2.07]

3 Global Rating (no change or improvement 24mg/d to 24‐32mg/d) ITT Show forest plot

6

2069

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.84 [1.53, 2.21]

4 Global Rating (no change or improvement 32‐36mg/d) ITT Show forest plot

4

1423

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.63 [1.31, 2.02]
Figuras y tablas -
Comparison 14. Global Rating dose analyses ITT
Ir a la tabla de la revisión
Comparison 15. Conversion from MCI to dementia (change of CDR‐SB from 0.5 to >=1) ITT

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

2 Conversion from MCI to dementia at 24 months Show forest plot

2

1903

Odds Ratio (M‐H, Fixed, 95% CI)

0.74 [0.58, 0.94]

2.1 galantamine (16‐24mg/d bid) vs placebo in MCI

2

1903

Odds Ratio (M‐H, Fixed, 95% CI)

0.74 [0.58, 0.94]
Figuras y tablas -
Comparison 15. Conversion from MCI to dementia (change of CDR‐SB from 0.5 to >=1) ITT
Ir a la tabla de la revisión
Comparison 16. Withdrawals before end of treatment

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Proportion of all cause discontinuations (3 months) Show forest plot

2

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

1.1 galantamine (18mg/d bid) vs placebo

1

175

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.03 [1.00, 4.13]

1.2 galantamine (24mg/d bid) vs placebo

1

143

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.75 [0.75, 4.08]

1.3 galantamine (24mg/d to 24‐32mg/d) vs placebo

1

386

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.42 [2.10, 5.58]

1.4 galantamine (36mg/d bid) vs placebo

1

141

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.79 [2.26, 10.14]

2 Proportion of discontinuations due to adverse events (3 months) Show forest plot

2

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

2.1 galantamine (18mg/d bid) vs placebo

1

175

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.57 [1.13, 5.83]

2.2 galantamine (24mg/d bid) vs placebo

1

143

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.99 [1.03, 8.64]

2.3 galantamine (24mg/d to 24‐32mg/d) vs placebo

1

386

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.11 [2.37, 7.13]

2.4 galantamine (36mg/d bid) vs placebo

1

141

Peto Odds Ratio (Peto, Fixed, 95% CI)

9.26 [4.05, 21.17]

3 Proportion of all cause discontinuations (6 months) Show forest plot

5

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

3.1 galantamine (8mg/d bid) vs placebo

1

426

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.57 [0.93, 2.65]

3.2 galantamine (16mg/d bid) vs placebo

1

565

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.43 [0.94, 2.18]

3.3 galantamine (16‐24mg/d bid) vs placebo

1

651

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.39 [0.95, 2.03]

3.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

640

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.24 [0.84, 1.83]

3.5 galantamine (24mg/d bid) vs placebo

3

1419

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.67 [1.29, 2.17]

3.6 galantamine (32mg/d bid) vs placebo

2

857

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.55 [1.87, 3.48]

3.7 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.36 [1.62, 3.45]

4 Proportion of discontinuations due to adverse events (6 months) Show forest plot

5

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

4.1 galantamine (8mg/d bid) vs placebo

1

426

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.92 [0.41, 2.04]

4.2 galantamine (16mg/d bid) vs placebo

1

565

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.97 [0.51, 1.86]

4.3 galantamine (16‐24mg/d bid) vs placebo

1

651

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.62 [0.85, 3.09]

4.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

644

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.94 [1.04, 3.59]

4.5 galantamine (24mg/d bid) vs placebo

3

1419

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.09 [1.51, 2.91]

4.6 galantamine (32mg/d bid) vs placebo

2

857

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.64 [2.56, 5.18]

4.7 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.79 [1.81, 4.28]
Figuras y tablas -
Comparison 16. Withdrawals before end of treatment
Ir a la tabla de la revisión
Comparison 17. Specific adverse events (3 months)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Proportion of subjects experiencing nausea (3 months) Show forest plot

2

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

1.1 galantamine (18mg/d bid) vs placebo

1

175

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.33 [1.64, 11.45]

1.2 galantamine (24‐32mg/d bid) vs placebo

2

529

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.32 [2.11, 5.21]

1.4 galantamine (36mg/d bid) vs placebo

1

141

Peto Odds Ratio (Peto, Fixed, 95% CI)

11.51 [4.61, 28.75]

2 Proportion of subjects experiencing vomiting (3 months) Show forest plot

2

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

2.1 galantamine (18mg/d bid) vs placebo

1

175

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.59 [1.39, 9.29]

2.2 galantamine (24‐32mg/d bid) vs placebo

2

529

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.14 [1.75, 5.63]

2.3 galantamine (36mg/d bid) vs placebo

1

141

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.19 [1.30, 13.48]

3 Proportion of subjects experiencing dizziness (3 months) Show forest plot

2

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

3.1 galantamine (18mg/d bid) vs placebo

1

175

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.33 [0.29, 6.00]

3.2 galantamine (24‐32mg/d bid) vs placebo

2

529

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.60 [1.39, 4.88]

3.3 galantamine (36mg/d bid) vs placebo

1

141

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.30 [0.48, 10.92]

4 Proportion of subjects experiencing diarrhea (3 months) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

4.1 galantamine (18mg/d bid) vs placebo

1

175

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.99 [0.14, 7.14]

4.2 galantamine (24‐32mg/d bid) vs placebo

1

143

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.46 [0.40, 15.20]

4.3 galantamine (36mg/d bid) vs placebo

1

141

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.66 [0.22, 12.73]

5 Proportion of subjects experiencing anorexia (3 months) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

5.1 galantamine (24‐32mg/d bid) vs placebo

1

386

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.24 [1.53, 6.88]

6 Proportion of subjects experiencing somnolence (3 months) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

6.1 galantamine (24‐32mg/d bid) vs placebo

1

386

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.78 [1.48, 9.67]

7 Proportion of subjects experiencing abdominal pain (3 months) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

7.1 galantamine (24‐32mg/d bid) vs placebo

1

386

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.93 [1.12, 7.66]

8 Proportion of subjects experiencing decreased appetite (3 months) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

8.1 galantamine (18mg/d bid) vs placebo

1

175

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.40 [0.53, 10.85]

8.2 galantamine (24‐32mg/d bid) vs placebo

1

143

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.59 [0.21, 12.11]

8.3 galantamine (36mg/d bid) vs placebo

1

141

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.47 [0.65, 18.56]

9 Proportion of subjects experiencing agitation (3 months) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

9.1 galantamine (24‐32mg/d bid) vs placebo

1

386

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.54 [1.25, 9.98]

10 Proportion of subjects experiencing headache (3 months) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

10.1 galantamine (18mg/d bid) vs placebo

1

175

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.25 [0.33, 4.75]

10.2 galantamine (24‐32mg/d bid) vs placebo

1

143

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.54 [0.69, 9.45]

10.3 galantamine (36mg/d bid) vs placebo

1

141

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.80 [1.36, 16.96]
Figuras y tablas -
Comparison 17. Specific adverse events (3 months)
Ir a la tabla de la revisión
Comparison 18. Specific adverse events (6 months)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Proportion of subjects experiencing nausea (6 months) Show forest plot

5

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

1.1 galantamine (8mg/d bid) vs placebo

1

426

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.28 [0.50, 3.26]

1.2 galantamine (16mg/d bid) vs placebo

1

565

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.94 [1.65, 5.25]

1.3 galantamine (16‐24mg/d bid) vs placebo

1

646

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.80 [1.65, 4.73]

1.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

639

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.39 [2.06, 5.57]

1.5 galantamine (24mg/d bid) vs placebo

3

1419

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.69 [2.82, 4.82]

1.6 galantamine (32mg/d bid) vs placebo

2

856

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.21 [1.66, 2.94]

1.7 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.58 [3.00, 6.98]

2 Proportion of subjects experiencing vomiting (6 months) Show forest plot

5

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

2.1 galantamine (8mg/d bid) vs placebo

1

426

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.85 [0.70, 11.62]

2.2 galantamine (16mg/d bid) vs placebo

1

565

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.70 [1.55, 8.85]

2.3 galantamine (16‐24mg/d bid) vs placebo

1

646

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.48 [1.76, 6.88]

2.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

639

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.85 [1.34, 6.08]

2.5 galantamine (24mg/d bid) vs placebo

3

1419

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.01 [2.15, 4.21]

2.6 galantamine (32mg/d bid) vs placebo

2

857

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.07 [2.09, 4.50]

2.7 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

6.33 [3.33, 12.03]

3 Proportion of subjects experiencing dizziness (6 months) Show forest plot

4

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

3.1 galantamine (8mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 galantamine (16mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.3 galantamine (16‐24mg/d bid) vs placebo

1

646

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.71 [0.89, 3.30]

3.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

639

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.40 [1.32, 4.34]

3.5 galantamine (24mg/d bid) vs placebo

2

860

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.62 [1.04, 2.52]

3.6 galantamine (32mg/d bid) vs placebo

2

857

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.04 [1.34, 3.11]

3.7 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.47 [1.03, 5.90]

4 Proportion of subjects experiencing diarrhea (6 months) Show forest plot

5

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

4.1 galantamine (8mg/d bid) vs placebo

1

426

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.84 [0.35, 2.01]

4.2 galantamine (16mg/d bid) vs placebo

1

565

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.14 [1.20, 3.80]

4.3 galantamine (16‐24mg/d bid) vs placebo

1

646

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.98 [0.53, 1.81]

4.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

639

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.67 [0.35, 1.30]

4.5 galantamine (24mg/d bid) vs placebo

3

1419

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.37 [0.91, 2.05]

4.6 galantamine (32mg/d bid) vs placebo

2

857

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.03 [1.35, 3.04]

4.7 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.14 [1.43, 6.89]

5 Proportion of subjects experiencing anorexia (6 months) Show forest plot

5

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

5.1 galantamine (8mg/d bid) vs placebo

1

426

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.95 [0.70, 5.47]

5.2 galantamine (16mg/d bid) vs placebo

1

565

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.06 [0.95, 4.47]

5.3 galantamine (16‐24mg/d bid) vs placebo

1

646

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.61 [1.25, 5.42]

5.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

639

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.35 [1.09, 5.07]

5.5 galantamine (24mg/d bid) vs placebo

3

1425

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.84 [1.24, 2.73]

5.6 galantamine (32mg/d bid) vs placebo

2

857

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.71 [2.95, 7.53]

5.7 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.47 [1.87, 10.68]

6 Proportion of subjects experiencing weight loss (6 months) Show forest plot

3

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

6.1 galantamine (8mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 galantamine (16mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.3 galantamine (16‐24mg/d bid) vs placebo

1

646

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.52 [1.48, 8.40]

6.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

639

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.14 [1.23, 8.01]

6.5 galantamine (24mg/d bid) vs placebo

2

860

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.55 [2.04, 6.17]

6.6 galantamine (32mg/d bid) vs placebo

2

857

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.98 [1.63, 5.46]

7 Proportion of subjects experiencing abdominal pain (6 months) Show forest plot

2

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

7.1 galantamine (8mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.2 galantamine (16mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

7.3 galantamine (24mg/d bid) vs placebo

1

425

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.59 [0.69, 3.68]

7.4 galantamine (32mg/d bid) vs placebo

1

424

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.60 [1.26, 5.33]

7.5 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.84 [1.05, 7.66]

8 Proportion of subjects experiencing tremor (6 months) Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

8.1 galantamine (8mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.2 galantamine (16mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

8.3 galantamine (24mg/d bid) vs placebo

1

425

Peto Odds Ratio (Peto, Fixed, 95% CI)

5.56 [1.77, 17.50]

8.4 galantamine (32mg/d bid) vs placebo

1

424

Peto Odds Ratio (Peto, Fixed, 95% CI)

4.64 [1.15, 18.77]

9 Proportion of subjects experiencing agitation (6 months) Show forest plot

3

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

9.1 galantamine (8mg/d bid) vs placebo

1

426

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.74 [0.92, 3.30]

9.2 galantamine (16mg/d bid) vs placebo

1

565

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.07 [0.61, 1.87]

9.3 galantamine (16‐24mg/d bid) vs placebo

1

646

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.93 [0.49, 1.75]

9.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

639

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.05 [0.57, 1.96]

9.5 galantamine (24mg/d bid) vs placebo

1

559

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.84 [0.47, 1.51]

9.6 galantamine (32mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

9.7 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.33 [0.58, 3.07]

10 Proportion of subjects experiencing headache (6 months) Show forest plot

3

Peto Odds Ratio (Peto, Fixed, 95% CI)

Subtotals only

10.1 galantamine (8mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

10.2 galantamine (16mg/d bid) vs placebo

0

0

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

10.3 galantamine (16‐24mg/d bid) vs placebo

1

646

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.98 [0.50, 1.92]

10.4 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

639

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.54 [0.84, 2.83]

10.5 galantamine (24mg/d bid) vs placebo

1

435

Peto Odds Ratio (Peto, Fixed, 95% CI)

2.83 [1.32, 6.09]

10.6 galantamine (32mg/d bid) vs placebo

1

433

Peto Odds Ratio (Peto, Fixed, 95% CI)

3.31 [1.61, 6.80]

10.7 galantamine (32mg/d tds) vs placebo

1

554

Peto Odds Ratio (Peto, Fixed, 95% CI)

1.02 [0.45, 2.30]
Figuras y tablas -
Comparison 18. Specific adverse events (6 months)
Ir a la tabla de la revisión
Comparison 19. Proportion of subjects deceased

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Proportion of subjects deceased ( 3 months) Show forest plot

2

940

Odds Ratio (M‐H, Fixed, 95% CI)

0.43 [0.10, 1.95]

1.1 galantamine (24‐32mg/d bid) vs placebo

1

386

Odds Ratio (M‐H, Fixed, 95% CI)

0.09 [0.00, 1.98]

1.2 galantamine (32mg/d tds) vs placebo

1

554

Odds Ratio (M‐H, Fixed, 95% CI)

1.01 [0.14, 7.25]

2 Proportion of subjects deceased ( 6 months) Show forest plot

4

4286

Odds Ratio (M‐H, Fixed, 95% CI)

0.95 [0.50, 1.78]

2.1 galantamine (16‐24mg/d bid ) vs placebo

1

651

Odds Ratio (M‐H, Fixed, 95% CI)

0.99 [0.06, 15.91]

2.2 galantamine (16‐24mg/d Prolonged Release ) vs placebo

1

644

Odds Ratio (M‐H, Fixed, 95% CI)

3.06 [0.32, 29.54]

2.3 galantamine (24mg/d bid) vs placebo

3

1576

Odds Ratio (M‐H, Fixed, 95% CI)

0.83 [0.35, 1.98]

2.4 galantamine (32mg/d bid or tds) vs placebo

1

424

Odds Ratio (M‐H, Fixed, 95% CI)

3.04 [0.12, 75.12]

2.5 galantamine (8mg/d bid) vs placebo

1

426

Odds Ratio (M‐H, Fixed, 95% CI)

0.51 [0.06, 4.58]

2.6 galantamine (16mg/d bid) vs placebo

1

565

Odds Ratio (M‐H, Fixed, 95% CI)

0.77 [0.17, 3.46]

3 Proportion of subjects deceased ( 24 months in MCI) Show forest plot

2

1903

Odds Ratio (M‐H, Fixed, 95% CI)

9.33 [1.72, 50.54]

3.1 galantamine (16‐24mg/d bid ) vs. placebo in MCI

2

1903

Odds Ratio (M‐H, Fixed, 95% CI)

9.33 [1.72, 50.54]
Figuras y tablas -
Comparison 19. Proportion of subjects deceased
Ir a la tabla de la revisión